AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced a significant licensing agreement with the SIFI Group. This deal grants AffaMed exclusive rights to manufacture, develop, and commercialize SIFI’s range of intraocular lens (IOL) products in the Greater China region. The financial details of the agreement have not been disclosed.
Exclusive Rights to SIFI’s IOL Products
Upon the finalization of the deal, AffaMed will obtain exclusive development, production, and commercialization rights for SIFI’s Mini Well, Mini Well Toric, Mini Well Proxa, Evolux, and Mini 4 Ready series IOLs in the Greater China market, which includes Chinese Mainland, Hong Kong, Macao, and Taiwan.
Evolux IOL: A New Frontier in Vision Care
Evolux is a groundbreaking extended single focal IOL that utilizes hydrophobic materials and a non-diffractive design. This innovation provides better mid-range vision while maintaining equivalent long-range vision compared to standard single focal IOLs. Developed on a patented technology platform, Evolux is the first to extend the depth of field through wavefront phase difference technology.
Optical Technology and Pupil Dependence
The optical technology applied in Evolux improves intermediate vision while preserving good long-range vision. The pupil dependence is minimal at both long and mid-range, and the imaging contrast remains similar under varying pupil sizes. Evolux also maintains the same level of safety in terms of tilt, eccentricity, and optical interference as standard single focus intraocular lenses and has a good tolerance for residual refractive errors.
Conclusion
The licensing agreement between AffaMed Technologies and SIFI Group is a strategic move that enhances AffaMed’s presence in the ophthalmic sector. With the exclusive rights to SIFI’s innovative IOL products, AffaMed is poised to offer advanced vision care solutions to the Greater China market.-Fineline Info & Tech
